January 14, 2016
Video
Plimack says the efficacy of PD-L1 inhibitors have been proven in the treatment of bladder cancer and are currently employed in the armamentarium of medical professionals. She adds as other cancer types further test both ipilimumab and PD-L1 inhibitors, oncologists will gain a better understanding of how both will continue to play a role in bladder cancer.
June 26, 2015
Video
Elizabeth Plimack, MD, MS, attending physician, genitourinary cancer associate professor, Medical Oncology Director of Genitourinary Clinical Research, Fox Chase Cancer Center, discusses a study that examined pembrolizumab in patients with urothelial cancer.
October 01, 2014
Article
Elizabeth Plimack, MD, MS, director, Genitourinary Clinical Research, Fox Chase Cancer Center, discusses a phase Ib study of pembrolizumab for the treatment of patients with bladder cancer.
February 04, 2014
Article
Elizabeth Plimack, MD, MS, attending physician, medical oncology, Fox Chase Cancer Center, discusses a phase I trial looking at overcoming mTOR resistance in renal cell carcinoma (RCC).